A5038660651- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Acute Lymphoblastic Leukemia research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Histone Deacetylase Inhibitors Research
- CAR-T cell therapy research
- Protein Degradation and Inhibitors
- Multiple Myeloma Research and Treatments
- Hematopoietic Stem Cell Transplantation
- Immune Cell Function and Interaction
- Cancer, Hypoxia, and Metabolism
- Retinoids in leukemia and cellular processes
- RNA Interference and Gene Delivery
- Epigenetics and DNA Methylation
- Immunotherapy and Immune Responses
- Cutaneous lymphoproliferative disorders research
- Cancer Genomics and Diagnostics
- Lymphoma Diagnosis and Treatment
- Neutropenia and Cancer Infections
- Toxin Mechanisms and Immunotoxins
- Hematological disorders and diagnostics
- Childhood Cancer Survivors' Quality of Life
- Immunodeficiency and Autoimmune Disorders
- Cancer therapeutics and mechanisms
Roswell Park Comprehensive Cancer Center
2016-2025
The University of Texas MD Anderson Cancer Center
2011-2023
New Zealand Association of Counsellors
2023
Fudan University
2023
Shanghai Jiao Tong University
2023
Bristol-Myers Squibb (Switzerland)
2023
Yale University
2023
Northside Hospital
2023
University of Pisa
2023
Istanbul University
2023
Acute myeloid leukemia (AML) is the most common form of acute among adults and accounts for largest number annual deaths due to leukemias in United States. This portion NCCN Guidelines AML focuses on management provides recommendations workup, diagnostic evaluation, treatment options younger (age <60 years) older ≥60 adult patients.
Expression of the human protooncogene bcl-2 protects neural cells from death induced by many forms stress, including conditions that greatly elevate intracellular Ca2+. Considering Bcl-2 is partially localized to mitochondrial membranes and excessive Ca2+ uptake can impair electron transport oxidative phosphorylation, present study tested hypothesis mitochondria Bcl-2-expressing have a higher capacity for energy-dependent greater resistance Ca(2+)-induced respiratory injury than do not...
Acute myeloid leukemia (AML) is the most common form of acute among adults and accounts for largest number annual deaths due to leukemias in United States. Recent advances have resulted an expansion treatment options AML, especially concerning targeted therapies low-intensity regimens. This portion NCCN Clinical Practice Guidelines Oncology (NCCN Guidelines) AML focuses on management provides recommendations workup, diagnostic evaluation younger (age <60 years) older ≥60 adult patients.
Abstract Gilteritinib is a potent and selective FLT3 kinase inhibitor with single-agent clinical efficacy in relapsed/refractory FLT3-mutated acute myeloid leukemia (AML). In this context, however, gilteritinib not curative, response duration limited by the development of secondary resistance. To evaluate resistance mechanisms, we analyzed baseline progression samples from patients treated on trials gilteritinib. Targeted next-generation sequencing at time AML identified treatment-emergent...
Blastic plasmacytoid dendritic-cell neoplasm (BPDCN) is an aggressive hematologic cancer that caused by transformed dendritic cells overexpress interleukin-3 receptor subunit alpha (IL3RA or CD123). Tagraxofusp (SL-401) a CD123-directed cytotoxin consisting of human fused to truncated diphtheria toxin.In this open-label, multicohort study, we assigned 47 patients with untreated relapsed BPDCN receive intravenous infusion tagraxofusp at dose 7 μg 12 per kilogram body weight on days 1 5 each...
Acute myeloid leukemia (AML) remains the most common form of acute among adults and accounts for largest number annual deaths due to leukemias in United States. The NCCN Clinical Practice Guidelines Oncology (NCCN Guidelines) AML provide recommendations on diagnostic evaluation workup AML, risk assessment based cytogenetic molecular features, treatment options induction consolidation therapies younger older (age ≥ 65 years) adult patients, key supportive care considerations.
Although azacitidine (AZA) improves survival in patients with high-risk myelodysplastic syndrome, the overall response remains approximately 50%. Entinostat is a histone deacetylase inhibitor that has been combined AZA significant clinical activity previous phase I dose finding study.Open label II randomized trial comparing 50 mg/m(2)/d given for 10 days ± entinostat 4 day 3 and 10. All subtypes of myelodysplasia, chronic myelomonocytic leukemia, acute myeloid leukemia myelodysplasia-related...
Treatment of acute lymphoblastic leukemia (ALL) continues to advance, as evidenced by the improved risk stratification patients and development newer treatment options. Identification ALL subtypes based on immunophenotyping cytogenetic molecular markers has resulted in inclusion Philadelphia-like early T-cell precursor that affect prognosis. Ikaros mutations also emerged a prognostic factor. In addition prognostication, options for with have expanded, particularly regard relapsed/refractory...
Abstract We conducted a phase I clinical trial of H3B-8800, an oral small molecule that binds Splicing Factor 3B1 (SF3B1), in patients with MDS, CMML, or AML. Among 84 enrolled (42 4 CMML and 38 AML), 62 were red blood cell (RBC) transfusion dependent at study entry. Dose escalation cohorts examined two once-daily dosing regimens: schedule (5 days on/9 off, range doses studied 1–40 mg, n = 65) II (21 on/7 7–20 19); 27 received treatment for ≥180 days. The most common treatment-related,...
Abstract The phase 3 ADMIRAL (NCT02421939; Study ID: 2215-CL-0301) trial showed superior overall survival in patients with relapsed/refractory FLT3-mutation–positive acute myeloid leukemia (AML) randomized 2:1 to receive the oral FMS-like tyrosine kinase inhibitor gilteritinib vs those salvage chemotherapy (SC). Here we provide a follow-up of 2 years after primary analysis clarify long-term treatment effects and safety these AML. At time this analysis, median was 37.1 months, deaths 203 247...
Treatment results for patients with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-mutated (FLT3mut+) acute myeloid leukemia (AML) ineligible intensive chemotherapy are disappointing. This multicenter, open-label, phase trial randomized (2:1) untreated adults FLT3mut+ AML induction to receive gilteritinib (120 mg/d orally) and azacitidine (GIL + AZA) or (AZA) alone. The primary end point was overall survival (OS). At the interim analysis (August 26, 2020), a total of 123 were treatment...
Magrolimab is a monoclonal antibody that blocks cluster of differentiation 47, don't-eat-me signal overexpressed on cancer cells. Cluster 47 blockade by magrolimab promotes macrophage-mediated phagocytosis tumor cells and synergistic with azacitidine, which increases expression eat-me signals. We report final phase Ib data in patients untreated higher-risk myelodysplastic syndromes (MDS) treated azacitidine (ClinicalTrials.gov identifier: NCT03248479).
Magrolimab is a first-in-class humanized monoclonal antibody against cluster of differentiation 47, an antiphagocytic signal used by cancer cells to evade phagocytosis. Azacitidine upregulates prophagocytic signals on AML cells, further increasing phagocytosis when combined with magrolimab. We report final phase Ib data for magrolimab azacitidine in patients untreated ineligible intensive chemotherapy (ClinicalTrials.gov identifier: NCT03248479).
Importance In newly diagnosed Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL), disease progression due to acquired resistance first- or second-generation BCR::ABL1 tyrosine kinase inhibitors is common. Ponatinib inhibits and all single-mutation variants, including T315I. Objective To compare frontline ponatinib vs imatinib in adults with Ph+ ALL. Design, Setting, Participants Global registrational, phase 3, open-label trial aged 18 years older From January 2019 May...
Crenolanib is a second-generation tyrosine kinase inhibitor with activity against
Olutasidenib is a potent, selective, oral, small molecule inhibitor of mutant IDH1 (mIDH1) which induced durable remissions in high-risk, relapsed/refractory (R/R) mIDH1 AML patients phase 1/2 trial. We present pooled analysis from multiple cohorts the trial with R/R who received combination olutasidenib and azacitidine therapy. Adult mIDH1R132 150 mg twice daily plus standard-of-care (OLU + AZA) were evaluated for response safety. Sixty-seven OLU AZA. Median age was 66 years (range 28-82)...